Advanced basal cell carcinoma treated with vismodegib

Published: 17 February 2020| Version 1 | DOI: 10.17632/bjv2bpjgv6.1
Contributor:
Christina Wong

Description

A. 64 yowf with nodular and micronodular BCC on back. Treated with vismodegib 150mg Mon-Fri with tumor shrinkage to 23 by 7cm after a six month course and treated subsequently with a radical resection and removal of T2-L1 spinous processes. Pt remains disease free after 52 months of treatment and surgery B. 63 yowf with infiltrative BCC arising in venous stasis ulcer on right foot. Treated with vismodegib 150mg/day for three months then was stopped by patient due to muscle cramps. Clinically no evidence of disease at 36 months after stopping vismodegib.

Files

Categories

Basal Cell Carcinoma, Vismodegib, Drug Delivery of Small Molecule

Licence